Inhibition of PLK1 abolished the oncogenic function of HN1L and enhanced the antitumor effect of chemotherapy, which suggests a potential therapeutic strategy for ESCC patients with high HN1L by combining PLK1 inhibitors and chemotherapy. The gene discussed is JPT2; the disease is esophageal squamous cell carcinoma.